Clinical Trial Update: An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy

View source ↗

Summary

An observational study comparing Delandistrogene Moxeparvovec with standard of care in Duchenne muscular dystrophy is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Delandistrogene moxeparvovec (delandistrogene moxeparvovec)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy | Status: ENROLLING_BY_INVITATION